Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .
Intake of Novel Red Clover Supplementation for 12 Weeks Improves Bone Status in Healthy Menopausal Women
Objective . To investigate the effect by which daily consumption of a novel red clover ( RC ) extract influences bone health , inflammatory status , and cardiovascular health in healthy menopausal women . Design . A 12-week r and omized , double-blinded , placebo-controlled trial involving 60 menopausal women receiving a daily dose of 150 mL RC extract containing 37.1 mg isoflavones ( 33.8 mg as aglycones ) or placebo . Methods . Bone parameters were changes in bone mineral density ( BMD ) , bone mineral content ( BMC ) , and T-score at the lumbar spine and femoral neck . Bone turnover ( CTx ) and inflammatory markers were measured in plasma and finally blood pressure ( BP ) was evaluated . Results . RC extract had positive effect on bone health , and only the women receiving the placebo experienced a decline in BMD ( p < 0.01 ) at the lumbar spine . T-score at the lumbar spine only decreased in the placebo group ( p < 0.01 ) . CTx decreased in the RC group with −9.94 (±4.93)% , although not significant . Conclusion . Daily consumption of RC extract over a 12-week period was found to have a beneficial effect on bone health  in menopausal women based on BMD and T-score at the lumbar spine and plasma CTx levels . No changes in BP or inflammation markers were found and no side effects were observed
Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .